Zydus Cadila gets DCGI’s nod for Saroglitazar Mg for treatment of Non-Alcoholic Fatty Liver Disease in India

30 Dec 2020 Evaluate

Zydus Cadila has received approval from the Drug Controller General of India (DCGI) for its New Drug Application (NDA) for Saroglitazar Mg for the treatment of Non-alcoholic Fatty Liver Disease (NAFLD) in India. The prevalence of NAFLD in India is estimated to be nearly 25-30% of the general population. This approval for NAFLD along with either of the comorbidities (Obesity, Type 2 Diabetes Mellitus, Dyslipidemia or Metabolic Syndrome) provides the physicians with a viable treatment option. With a once daily, 4mg dose regimen, Saroglitazar Mg will enable better compliance, reduces the pill burden and offers the patient more convenience.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

889.95 -0.25 (-0.03%)
30-Jan-2026 09:19 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1591.00
Dr. Reddys Lab 1216.00
Cipla 1323.00
Zydus Lifesciences 889.95
Lupin 2151.55
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×